Report
Jacob Mekhael

Zealand Pharma Completes petrelintide phase 2b enrolment in obesity/overweight

Zealand announced that the last participant has been enrolled and randomised in the phase 2b (ZUPREME-1) trial of petrelintide (long acting amylin analog, SC) in people with obesity or overweight with weight-related comorbidities. While the company has not provided specific guidance for when results will be released, we expect this to be around 1Q26 taking into account the 42 week treatment period. We reiterate our DKK 970 TP and BUY rating.
Underlying
Zealand Pharma A/S

Zealand Pharma is a biotechnology company. Co. is engaged in the discovery development and commercialization of peptide-based medicines. Co.'s pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and obesity treatment, such as Lyxumia (Lixisenatide), Lyxumia/Lantus, ZP2929 and Danegaptide. The Other indications area are ZP1848, Elsiglutide and ZP1480 (ABT-719) drugs for inflammatory bowel disease, chemotherapy-induced diarrhea and acute kidney injury treatment.

Provider
KBC Securities
KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

 

Analysts
Jacob Mekhael

Other Reports on these Companies
Other Reports from KBC Securities

ResearchPool Subscriptions

Get the most out of your insights

Get in touch